Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

(2021) Charlotte Manisty et al.   LANCET

Evaluation of Immune and Vaccine Competence in Steroid-Sensitive Nephrotic Syndrome Pediatric Patients

(2021) Manuela Colucci et al.   Frontiers in Immunology

Early antibody response in healthcare professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

(2021) Julien Favresse et al.   CLINICAL MICROBIOLOGY AND INFECTION

Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID‐19 mRNA vaccine

(2021) Mikiko Watanabe et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines

(2021) Johanna Chapin-Bardales et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers

(2021) Marie Tré-Hardy et al.   JOURNAL OF INFECTION

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

(2021) Victoria Jane Hall et al.   LANCET

Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers

(2021) Andrea Padoan et al.   CLINICA CHIMICA ACTA

Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study

(2021) Wan Ni Chia et al.   Lancet Microbe

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

(2020) Alicia T. Widge et al.   NEW ENGLAND JOURNAL OF MEDICINE